Clinical trial
Pediatrics Testotoxicosis Study [Bicalutamide Anastrozole Treatment for…
NCT00094328 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00094328 |
|---|---|
| Title | Pediatrics Testotoxicosis Study [Bicalutamide Anastrozole Treatment for Testotoxicosis] |
| Official title | An Open-label, Non-comparative, Multi-centre Study to Assess the Efficacy and Safety of Bicalutamide When Used in Combination With Anastrozole for the Treatment of Gonadotropin-independent Precocious Puberty in Boys With Testotoxicosis |
| Acronym | BATT |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Puberty, Precocious |
| Intervention type | Drug |
| Interventions | Bicalutamide, Anastrozole |
| Enrollment | 14 |
| Start date | Nov 22, 2004 |
| Primary completion | May 22, 2008 |
| Completion | Dec 6, 2017 |
| First posted | Oct 18, 2004 |
| Last update posted | Jun 26, 2018 |
| Countries | Canada, France, India, Russia, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: